PassPort Technologies announced the initiation of a collaborative research endeavor with Arcturus Therapeutics (ARCT). “This research collaboration is focused on evaluating innovative mRNA formulations and transdermal delivery mechanisms for vaccines and therapeutics. The research collaboration will leverage ARCT’s expertise in mRNA design and proprietary LUNAR platform technologies, alongside PPTI’s groundbreaking PassPort transdermal drug delivery technology. PPTI will utilize its unique platform technology and extensive knowledge in transdermal biologics and oligonucleotides delivery. ARCT will supply select mRNA and LUNAR formulations, which PPTI will subsequently adapt to the PassPort system,” PassPort stated.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARCT:
- The biotech stocks to own in 2024, according to Piper Sandler
- Arcturus Therapeutics and CSL’ ARCT-154 shows superior immunogenicity
- Arcturus Therapeutics, CSL publish data on booster dose of ARCT-154
- Arcturus Therapeutics initiated with bullish view at Canaccord, here’s why
- Arcturus Therapeutics initiated with bullish view at Canaccord
